Enobia Pharma Corp.

2901, Rachel Street East, #23,
Montreal, Quebec H1W 4A4

Enobia, which is based in Montreal and Cambridge, Mass., focuses on development of therapies for patients with genetic metabolic bone disorders. Enobia's lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs.

Enobia Pharma was acquired by Alexion Pharmaceuticals on February 08, 2012.

Join Mergr to view all 12 acquisitions of companies in 2012, including 8 acquisitions by private equity firms, and 4 by strategics.

Out of 60 sectors in the Mergr database, ranked 56 in number of deals in 2012. The largest acquisition in 2012 was Enobia Pharma - which was acquired by Alexion Pharmaceuticals for $1.1B.

Join Mergr to view this profile - and discover more acquisitions of companies like Enobia Pharma.

What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
  • 3.4K Private Equity Firms
  • 117K M&A Transactions
  • 127K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.8K M&A Advisors
    (Investment Banks and Law Firms)
  • 36K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.